Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish National Health System: influence and implications

Axel Leporowski, Brian Godman, Amanj Kurdi, Sean MacBride-Stewart, Margaret Ryan, Simon Hurding, Renata CRM do Nascimento, Marion Bennie, Alec Morton

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction and aims: Prescribing of lipid lowering agents (LLAs) has increased worldwide including in Scotland with increasing prevalence of coronary heart disease, and higher dose statins have been advocated in recent years. There have also been initiatives to encourage prescribing of generic versus patented statins to save costs without compromising care. There is a need to document these initiatives and outcomes to provide future direction. Method: Assessment of utilization (items dispensed) and expenditure of key LLAs (mainly statins) and expenditure between 2001 and 2015 in Scotland alongside initiatives. Results: Multiple interventions have increased international non-proprietary name (INN) prescribing (99% for statins) and preferential prescribing of generic versus patented statins, and reduced inappropriate prescribing of ezetimibe. This resulted in a 50% reduction in LLA expenditure between 2001 and 2015 despite a 412% increase in utilization, increased prescribing of higher dose statins (71% in 2015) especially atorvastatin following generic availability, and reduced prescribing of ezetimibe (reduced by 72% between 2010 and 2015). As a result, the quality of prescribing has improved. Conclusion: Generic availability coupled with multiple measures has resulted in appreciable shifts in statin prescribing behavior and reducing ezetimibe prescribing, resulting in improvements in both the quality and efficiency of prescribing.
LanguageEnglish
Pages655-666
Number of pages12
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume18
Issue number6
Early online date3 Aug 2018
DOIs
Publication statusPublished - 10 Oct 2018

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipids
Health
Health Expenditures
Scotland
Inappropriate Prescribing
Names
Coronary Disease
Costs and Cost Analysis

Keywords

  • lipid lowering agents
  • Scottish NHS
  • expenditure
  • reforms
  • drug utilisation

Cite this

@article{cf1960ef24f4410ebef087083ffd7ca9,
title = "Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish National Health System: influence and implications",
abstract = "Introduction and aims: Prescribing of lipid lowering agents (LLAs) has increased worldwide including in Scotland with increasing prevalence of coronary heart disease, and higher dose statins have been advocated in recent years. There have also been initiatives to encourage prescribing of generic versus patented statins to save costs without compromising care. There is a need to document these initiatives and outcomes to provide future direction. Method: Assessment of utilization (items dispensed) and expenditure of key LLAs (mainly statins) and expenditure between 2001 and 2015 in Scotland alongside initiatives. Results: Multiple interventions have increased international non-proprietary name (INN) prescribing (99{\%} for statins) and preferential prescribing of generic versus patented statins, and reduced inappropriate prescribing of ezetimibe. This resulted in a 50{\%} reduction in LLA expenditure between 2001 and 2015 despite a 412{\%} increase in utilization, increased prescribing of higher dose statins (71{\%} in 2015) especially atorvastatin following generic availability, and reduced prescribing of ezetimibe (reduced by 72{\%} between 2010 and 2015). As a result, the quality of prescribing has improved. Conclusion: Generic availability coupled with multiple measures has resulted in appreciable shifts in statin prescribing behavior and reducing ezetimibe prescribing, resulting in improvements in both the quality and efficiency of prescribing.",
keywords = "lipid lowering agents, Scottish NHS, expenditure, reforms, drug utilisation",
author = "Axel Leporowski and Brian Godman and Amanj Kurdi and Sean MacBride-Stewart and Margaret Ryan and Simon Hurding and {do Nascimento}, {Renata CRM} and Marion Bennie and Alec Morton",
year = "2018",
month = "10",
day = "10",
doi = "10.1080/14737167.2018.1501558",
language = "English",
volume = "18",
pages = "655--666",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
number = "6",

}

Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish National Health System : influence and implications. / Leporowski, Axel; Godman, Brian; Kurdi, Amanj; MacBride-Stewart, Sean; Ryan, Margaret ; Hurding, Simon; do Nascimento, Renata CRM; Bennie, Marion; Morton, Alec.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 18, No. 6, 10.10.2018, p. 655-666.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish National Health System

T2 - Expert Review of Pharmacoeconomics and Outcomes Research

AU - Leporowski, Axel

AU - Godman, Brian

AU - Kurdi, Amanj

AU - MacBride-Stewart, Sean

AU - Ryan, Margaret

AU - Hurding, Simon

AU - do Nascimento, Renata CRM

AU - Bennie, Marion

AU - Morton, Alec

PY - 2018/10/10

Y1 - 2018/10/10

N2 - Introduction and aims: Prescribing of lipid lowering agents (LLAs) has increased worldwide including in Scotland with increasing prevalence of coronary heart disease, and higher dose statins have been advocated in recent years. There have also been initiatives to encourage prescribing of generic versus patented statins to save costs without compromising care. There is a need to document these initiatives and outcomes to provide future direction. Method: Assessment of utilization (items dispensed) and expenditure of key LLAs (mainly statins) and expenditure between 2001 and 2015 in Scotland alongside initiatives. Results: Multiple interventions have increased international non-proprietary name (INN) prescribing (99% for statins) and preferential prescribing of generic versus patented statins, and reduced inappropriate prescribing of ezetimibe. This resulted in a 50% reduction in LLA expenditure between 2001 and 2015 despite a 412% increase in utilization, increased prescribing of higher dose statins (71% in 2015) especially atorvastatin following generic availability, and reduced prescribing of ezetimibe (reduced by 72% between 2010 and 2015). As a result, the quality of prescribing has improved. Conclusion: Generic availability coupled with multiple measures has resulted in appreciable shifts in statin prescribing behavior and reducing ezetimibe prescribing, resulting in improvements in both the quality and efficiency of prescribing.

AB - Introduction and aims: Prescribing of lipid lowering agents (LLAs) has increased worldwide including in Scotland with increasing prevalence of coronary heart disease, and higher dose statins have been advocated in recent years. There have also been initiatives to encourage prescribing of generic versus patented statins to save costs without compromising care. There is a need to document these initiatives and outcomes to provide future direction. Method: Assessment of utilization (items dispensed) and expenditure of key LLAs (mainly statins) and expenditure between 2001 and 2015 in Scotland alongside initiatives. Results: Multiple interventions have increased international non-proprietary name (INN) prescribing (99% for statins) and preferential prescribing of generic versus patented statins, and reduced inappropriate prescribing of ezetimibe. This resulted in a 50% reduction in LLA expenditure between 2001 and 2015 despite a 412% increase in utilization, increased prescribing of higher dose statins (71% in 2015) especially atorvastatin following generic availability, and reduced prescribing of ezetimibe (reduced by 72% between 2010 and 2015). As a result, the quality of prescribing has improved. Conclusion: Generic availability coupled with multiple measures has resulted in appreciable shifts in statin prescribing behavior and reducing ezetimibe prescribing, resulting in improvements in both the quality and efficiency of prescribing.

KW - lipid lowering agents

KW - Scottish NHS

KW - expenditure

KW - reforms

KW - drug utilisation

UR - https://tandfonline.com/toc/ierp20/current

U2 - 10.1080/14737167.2018.1501558

DO - 10.1080/14737167.2018.1501558

M3 - Article

VL - 18

SP - 655

EP - 666

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 6

ER -